Overview

• The $499 monthly price applies to uninsured or underinsured U.S. patients purchasing Ozempic or Wegovy through GoodRx or NovoCare at over 70,000 participating pharmacies.
• Novo Nordisk emphasizes the move as a strategy to increase access to authentic FDA-approved semaglutide treatments and discourage use of potentially unsafe compounded alternatives.
• The announcement prompted a near 5% jump in Novo Nordisk shares and a nearly 40% surge in GoodRx stock on investor optimism over its market impact.
• Most insured U.S. diabetes patients already pay about $25 per month for Ozempic under existing coverage, leaving the new program focused on cash-pay populations.
• The price cut responds to competitive pressure from rivals like Eli Lilly and ongoing U.S. political scrutiny over high drug prices, even as broader insurance and Medicare negotiation challenges remain unresolved.